Current Progress and Development of Cancer Vaccines
DOI:
https://doi.org/10.61173/29kj9d65Keywords:
Cancer vaccine, immunotherapy, oncology, tumor microenvironmentAbstract
mwymwAbstract:Due to the accumulation of DNA damage over time, an increased human lifespan leads to higher cancer incidence and mortality rates, leading to the need for more effective prevention and treatment strategies. Cancer vaccines are emerging as an innovative and promising type of immunotherapy, offering the potential for personalized, less toxic treatments that enhance long-term immune surveillance and response. This review delves into the cutting-edge progress of cancer vaccine development, emphasizing their unique ability to empower the immune system to detect and destroy cancer. Despite significant progress, the development of these vaccines faces daunting challenges related to tumor diversity, immune suppression and evasion, and the complexity of vaccine production. The use of new technologies, including artificial intelligence and genomics, may be the key to overcoming these barriers. This paper explores how innovation is pushing the boundaries of what’s possible in the fight against this unforgiving disease. The future of cancer therapy may just lie in a shot of hope.References
[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–49.
[2] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024;74(1):12–49.
[3] Chiang CLL, Kandalaft LE. Chapter 2 - Tumor lysates cancer vaccine. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Aug 24]. p. 21–49. Available from: https://www.sciencedirect.com/science/article/pii/ B9780128239018000017
[4] Abbott M, Ustoyev Y. Cancer and the Immune System: The History and Background of Immunotherapy. Seminars in Oncology Nursing. 2019 Oct 1;35(5):150923.
[5] Liu N, Xiao X, Zhang Z, Mao C, Wan M, Shen J. Advances in Cancer Vaccine Research. ACS Biomater Sci Eng. 2023 Nov 13;9(11):5999–6023.
[6] Jacqueline C, Finn OJ. Chapter 3 - Tumor antigens for preventative cancer vaccines. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Aug 24]. p. 51–74. Available from: https://www.sciencedirect.com/science/article/ pii/B9780128239018000066
[7] Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley AG, McArdle SEB. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Frontiers in Immunology [Internet]. 2021 Feb 17 [cited 2024 Aug 24];11. Available from: https://www.frontiersin.org/journals/ immunology/articles/10.3389/fimmu.2020.615240/full
[8] Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal of Leukocyte Biology. 2020 Oct 1;108(4):1455–89.
[9] Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, et al. Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review. Cells. 2023;12(17):2159.
[10] Tiwari A, Alcover K, Carpenter E, Thomas K, Krum J, Nissen A, et al. Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis. Human Vaccines & Immunotherapeutics. 2024 Dec 31;20(1):2323256.
[11] Munson PV, Butterfield LH, Adamik J. Chapter 7 - Novel dendritic cell vaccine strategies. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Sep 8]. p. 109–35. Available from: https://www.sciencedirect.com/science/article/ pii/B9780128239018000030
[12] Lee KW, Yam JWP, Mao X. Dendritic Cell Vaccines: A Dean&Francis ISSN 2959-409X Shift from Conventional Approach to New Generations. Cells. 2023 Jan;12(17):2147.
[13] Kishi M, Asgarova A, Desterke C, Chaker D, Artus J, Turhan AG, et al. Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy. Front Med [Internet]. 2021 Dec 10 [cited 2024 Sep 9];8. Available from: https://www.frontiersin. org/journals/medicine/articles/10.3389/fmed.2021.729018/full
[14] Yan F, Cowell LG, Tomkies A, Day AT. Therapeutic Vaccination for HPV-Mediated Cancers. Curr Otorhinolaryngol Rep. 2023 Mar 1;11(1):44–61.
[15] Tseha ST. Role of Adenoviruses in Cancer Therapy. Front Oncol [Internet]. 2022 Jun 9 [cited 2024 Sep 14];12. Available from: https://www.frontiersin.org/journals/oncology/ articles/10.3389/fonc.2022.772659/full
[16] Stachura P, Stencel O, Lu Z, Borkhardt A, Pandyra AA. Arenaviruses: Old viruses present new solutions for cancer therapy. Front Immunol [Internet]. 2023 Mar 24 [cited 2024 Sep 14];14. Available from: https://www.frontiersin.org/journals/ immunology/articles/10.3389/fimmu.2023.1110522/full
[17] Zhou M, Tang Y, Xu W, Hao X, Li Y, Huang S, et al. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. Front Immunol [Internet]. 2023 Aug 3 [cited 2024 Sep 14];14. Available from: https:// www.frontiersin.org/journals/immunology/articles/10.3389/ fimmu.2023.1140463/full
[18] Zhang Y, Ma JA, Zhang HX, Jiang YN, Luo WH. Cancer vaccines: Targeting KRAS-driven cancers. Expert Review of Vaccines. 2020 Feb 1;19(2):163–73.
[19] Hamilton DH, Schlom J, Jochems C. Chapter 9 - Peptidebased vaccines. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Aug 24]. p. 155–73. Available from: https://www.sciencedirect.com/science/article/pii/ B978012823901800008X
[20] Conforti A, Palombo F, Aurisicchio L. Chapter 13 - Nucleic acid-based vaccines. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Aug 24]. p. 227–45. Available from: https://www.sciencedirect.com/science/article/pii/ B9780128239018000029
[21] Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020 Jan 14;52(1):17-35.
[22] Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Sig Transduct Target Ther. 2023 Dec 13;8(1):1–23.
[23] Depil S, Bonaventura P, Alcazer V. Cancer vaccines: what’s next? Oncotarget. 2019 Jun 18;10(40):3985–7.
[24] Redwood AJ, Dick IM, Creaney J, Robinson BWS. What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. OncoImmunology. 2022 Dec 31;11(1):2038403.
[25] Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020 Jun;30(6):507-19.
[26] Maserat E. Integration of Artificial Intelligence and CRISPR/Cas9 System for Vaccine Design. Cancer Inform. 2022 Jan 1;21:11769351221140102.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
